Cargando…

Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis

Background and Aims: Exercise remains a key component of nonalcoholic fatty liver disease (NAFLD) treatment. However, mechanisms underpinning the improvements in NAFLD seen with exercise are unclear. Exercise improved liver fat and serum biomarkers of liver fibrosis in the NASHFit trial. We investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stine, Jonathan G., Welles, Jaclyn E., Keating, Shelley, Hussaini, Zeba, Soriano, Christopher, Heinle, J. Wes, Geyer, Nathaniel, Chinchilli, Vernon M., Loomba, Rohit, Kimball, Scot R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056327/ https://www.ncbi.nlm.nih.gov/pubmed/36986211 http://dx.doi.org/10.3390/nu15061481

Ejemplares similares

Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms
por: Heinle, James Westley, et al.
Publicado: (2023)

MRI‐Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis
por: Loomba, Rohit
Publicado: (2021)

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
por: Sinakos, Emmanouil, et al.
Publicado: (2022)

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
por: Kim, Young Seok, et al.
Publicado: (2013)

Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis
por: Sharpton, Suzanne R., et al.
Publicado: (2022)

Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression
por: Du, Kuo, et al.
Publicado: (2019)

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
por: Brennan, Paul N., et al.
Publicado: (2023)

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
por: Alkhouri, Naim, et al.
Publicado: (2021)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH
por: Stine, Jonathan G., et al.
Publicado: (2020)

High-intensity Interval Training for the Management of Nonalcoholic Steatohepatitis: Participant Experiences and Perspectives
por: Keating, Shelley E., et al.
Publicado: (2023)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Le, Thuy-Anh, et al.
Publicado: (2012)

Utilization of a Directly Supervised Telehealth-Based Exercise Training Program in Patients With Nonalcoholic Steatohepatitis: Feasibility Study
por: Motz, Victoria, et al.
Publicado: (2021)

Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis
por: Ando, Wataru, et al.
Publicado: (2018)

The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis
por: Sanyal, Arun, et al.
Publicado: (2023)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
por: Sinha, Rohit A., et al.
Publicado: (2020)

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
por: Friedman, Scott L., et al.
Publicado: (2018)

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
por: Dufour, Jean-François, et al.
Publicado: (2020)

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
por: Loomba, Rohit, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko, Yuya, et al.
Publicado: (2018)

High-Intensity Interval Training is Safe, Feasible and Efficacious in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
por: Keating, Shelley E., et al.
Publicado: (2022)

An integrative approach to assessing effects of a short-term Western diet on gene expression in rat liver
por: Welles, Jaclyn E., et al.
Publicado: (2022)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
por: Hartman, Mark L., et al.
Publicado: (2020)

Wilson's disease masquerading as nonalcoholic steatohepatitis
por: Mahmood, Sabina, et al.
Publicado: (2009)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
por: Lam, Mindy C.W., et al.
Publicado: (2012)

The effect of β-caryophyllene on nonalcoholic steatohepatitis
por: Arizuka, Naoya, et al.
Publicado: (2017)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

The regulatory state of nonalcoholic steatohepatitis and metabolism
por: Omokaro, Stephanie O., et al.
Publicado: (2020)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5tchcn71gi4o37hprp3o7utfpc